Fig. 3

The chemical depletion of CCDC6 gene product by P5091, sensitizes ovarian carcinoma cells to the PARP inhibitor olaparib alone or in combination with cisplatin. (A, D, G, left side): Drugs sensitivity to Olaparib, PARG inhibitor (PARGi) and Cisplatin, in presence or absence of P5091 [2.5 μM] was determined by a modified 3-(4,5-dimethylthiazole-2- yl)-2–5-diphenyltetrazolium bromide assay, CellTiter 96 Aqueous One Solution assay (Promega), and was expressed as 50% inhibitory concentration (IC50) values. (A, D, G, right side): Surviving fractions of Kuramochi, OVCAR3 and OV-90 cells treated for 144 h, in presence or absence of P5091 [2.5 μM], with different doses of Olaparib, PARG inhibitor and Cisplatin. (B, E, H) The combination index values (CI) according to 1:2 concentration ratio of Cisplatin and Olaparib, in presence or absence of P5091 [2.5 μM] are shown. (C, F, I, left side): Drugs sensitivity to the PARP inhibitors Talazoparib and Veliparib, in presence or absence of P5091 [2.5 μM] are displayed. (C, F, I, right side) Surviving fractions of Kuramochi, OVCAR3 and OV-90 cells treated for 144 h, in presence or absence of P5091 [2.5 μM], with different doses of Talazoparib and Veliparib, were determined and expressed as in (A, D, G, right side)